Crystal's MCW Coder Hub🧬 ICD-10-CM H40.61X2 — Glaucoma Secondary to Drugs, Right Eye, Moderate Stage
Billable Code Confirmed — 7 Characters Complete
ICD-10 CM H40.61X2 is a valid, billable 7-character ICD-10-CM code for FY2025. Structure:
H40(glaucoma) +.6(secondary to drugs) +1(right eye) +X(structural placeholder) +2(moderate stage). Complete and current.
Non-Billable Parent Codes — Do Not Submit
- ❌
H40.61— 5-character header — non-billable; missing X + stage- ❌
H40.6— 4-character header — non-billable subcategory
🚨 MANDATORY ADDITIONAL CODE — T-Code Required
Same instruction as H40.61X1 — “Use additional code for adverse effect, if applicable, to identify drug (T36–T50 with fifth or sixth character 5).” T38.0X5D (glucocorticoids, subsequent encounter) is required on every monitoring claim. T38.0X5A at the initial moderate-stage diagnosis visit only. Never submit H40.61X2 as a standalone code.
Cross-Reference Note
For full pathophysiology, T-code mechanics, steroid responder background, route-of-administration risk, CPT templates, and adverse effect vs. poisoning distinction → see H40.61X1. This note focuses on what is clinically and operationally different at moderate stage.
🔍 Code Description
ICD-10 CM H40.61X2 classifies glaucoma secondary to drug therapy, right eye, at the moderate stage — the middle tier of glaucomatous damage in the H40.61Xx family, representing measurable, clinically significant visual field loss that crosses the -6 dB threshold but does not yet reach the severe damage (-12 dB) or threaten central fixation. At this stage, the patient typically has awareness of peripheral vision changes, and the clinical decision-making shifts meaningfully toward more aggressive IOP control, closer monitoring intervals, and often procedural intervention.
The moderate stage is a pivotal coding and clinical milestone. It is the point at which AREDS2 for AMD analogy holds — just as intermediate AMD drives supplementation decisions, moderate drug-induced glaucoma drives the surgical threshold conversation for SLT, MIGS, or trabeculectomy. Accurate staging here directly influences medical necessity documentation for any procedural intervention billed alongside or after this diagnosis.
📊 Moderate Stage — Defining Criteria and What Changed from Mild
The Single Most Important Threshold — MD Crosses -6 dB
| Feature | Mild — H40.61X1 | Moderate — H40.61X2 | Severe — H40.61X3 |
|---|---|---|---|
| HVF Mean Deviation | Better than -6 dB | -6 to -12 dB | Worse than -12 dB |
| Field loss location | Early paracentral/nasal | Respects horizontal meridian; not within 5° of fixation in BOTH hemifields | Within 5° of fixation in ≥1 hemifield |
| OCT RNFL | Early thinning | Moderate thinning — clear sector loss | Advanced thinning/loss |
| Central VA | Preserved (20/20–20/30) | Usually still preserved — but functional impact begins | Threatened or reduced |
| Functional impact | Minimal — patient often unaware | Patient may notice peripheral vision gaps; driving safety discussion | Significant functional loss |
| Monitoring frequency | Every 6–12 months HVF | Every 3–6 months HVF; every 6 months OCT | Every 3 months HVF and OCT |
| Surgical threshold | SLT consideration | Strong SLT/MIGS consideration; trabeculectomy if IOP uncontrolled | Urgent surgical intervention |
| Target IOP | 18–22 mmHg typical | Lower target — 15–18 mmHg; 30%+ reduction from baseline | Aggressive — often <15 mmHg |
🌳 Stage Context in the Full H40.61X Family
H40.61 Right Eye — Glaucoma Secondary to Drugs ❌ Non-billable
│
├── H40.61X0 Stage unspecified ⚠️ Query — avoid
├── H40.61X1 Mild — MD > -6 dB — early field loss
├── H40.61X2 MODERATE — MD -6 to -12 — significant field loss ← THIS CODE ✅
├── H40.61X3 Severe — MD < -12 dB — advanced field loss, central threat
└── H40.61X4 Indeterminate — cannot be staged
Staging at Moderate — Document the HVF MD Value in the Note
The clearest way to defend moderate-stage coding is a documented HVF 24-2 MD value between -6 and -12 dB in the physician note or the attached visual field report. When the physician writes “moderate glaucoma” without documenting the MD, CDI can be supported by the attached HVF printout — but physician confirmation of stage is always cleanest. If there is no HVF available (media opacity, poor patient cooperation) → consider H40.61X4 (indeterminate) rather than forcing a stage assignment.
💊 Management Implications at Moderate Stage
Moderate-stage drug-induced glaucoma carries significantly higher clinical urgency than mild stage. The documentation in the record should reflect this shift.
IOP Target Change
| Stage | Typical IOP Target | Rationale |
|---|---|---|
| Mild | 18–22 mmHg (≥20% reduction) | Early damage — moderate reduction sufficient |
| Moderate | 15–18 mmHg (≥30% reduction) | Significant damage — more aggressive target |
| Severe | <15 mmHg (≥40% reduction) | Advanced damage — tight control mandatory |
Medication Escalation at Moderate Stage
When a patient progresses from H40.61X1 to H40.61X2, medical therapy is typically intensified:
| Step | Typical Regimen |
|---|---|
| Step 1 | Prostaglandin analogue (latanoprost, bimatoprost, travoprost) monotherapy |
| Step 2 | + Beta-blocker (timolol) or alpha-agonist (brimonidine) |
| Step 3 | + Carbonic anhydrase inhibitor (dorzolamide, brinzolamide) |
| Step 4 | Combination drops or fixed-dose combinations — or consider SLT/MIGS at moderate |
Steroid Discontinuation Is Still the Primary Intervention
At any stage of H40.61X1–3, the first-line management remains discontinuing or reducing the causative steroid when clinically feasible. At moderate stage, the urgency to switch to a steroid-sparing alternative (e.g., topical NSAID instead of steroid post-op, anti-VEGF instead of Ozurdex, methotrexate instead of prednisone) is significantly higher than at mild. Document the clinical decision: “steroid cannot be discontinued due to [underlying condition] — managing with IOP-lowering therapy.”
Procedural Interventions at Moderate Stage
The moderate stage is where laser and surgical intervention enters the medical necessity documentation:
| Procedure | CPT | ICD-10-CM Support |
|---|---|---|
| Selective laser trabeculoplasty (SLT) | 65855-RT | H40.61X2 supports medical necessity for SLT |
| iStent / Hydrus (MIGS at cataract surgery) | 0191T, 0253T | H40.61X2 + cataract code support MIGS necessity |
| Trabeculectomy | 66170-RT, 66172-RT | Typically reserved for severe unless IOP uncontrolled at moderate |
| Tube shunt (Ahmed, Baerveldt) | 66180-RT | Refractory cases — moderate with failed medical/laser |
| Cycloablation (CPC) | 66711-RT | Refractory — moderate with poor surgical candidates |
MIGS + Cataract — The Moderate Stage Sweet Spot
ICD-10 CM H40.61X2 is frequently seen on claims where MIGS (minimally invasive glaucoma surgery) is performed concurrently with cataract extraction. Moderate stage is the ideal entry point for MIGS — enough damage to justify intervention, not so advanced that MIGS alone won’t suffice. The iStent inject, Hydrus, or Kahook Dual Blade require documentation of glaucoma severity to justify the procedure. H40.61X2 with documented MD in the -6 to -12 dB range and inadequate IOP control on maximum tolerated medical therapy provides strong medical necessity support.
🔗 Related ICD-10-CM Codes
Direct Family — Same Drug Cause, Right Eye
| Code | Description | MD Threshold |
|---|---|---|
| H40.61X0 | Right eye, stage unspecified | Not documented ⚠️ |
| H40.61X1 | Right eye, mild stage | Better than -6 dB |
| H40.61X2 | Right eye, moderate stage ← This Code | -6 to -12 dB |
| H40.61X3 | Right eye, severe stage | Worse than -12 dB |
| H40.61X4 | Right eye, indeterminate stage | Cannot be staged |
Cross-Laterality
| Code | Description |
|---|---|
| H40.62X2 | Glaucoma secondary to drugs, left eye, moderate stage |
| H40.63X2 | Glaucoma secondary to drugs, bilateral, moderate stage |
Primary vs. Drug-Induced — Moderate Right Eye
| Code | Description |
|---|---|
| H40.1112 | Primary open-angle glaucoma, right eye, moderate — no drug cause |
| H40.61X2 | Drug-induced glaucoma, right eye, moderate ← This Code |
Mandatory Additional Code
| Code | Description | Use When |
|---|---|---|
| T38.0X5A | Adverse effect glucocorticoids, initial encounter | First visit documenting moderate stage |
| T38.0X5D | Adverse effect glucocorticoids, subsequent encounter | All ongoing monitoring visits ← Most common |
Common Co-Codes at Moderate Stage
| Code | Description | Relevance |
|---|---|---|
| Z79.52 | Long-term current use of systemic steroids | Chronic steroid exposure documentation |
| H26.13 | Posterior subcapsular cataract | Steroid-induced PSC — concurrent with SIG |
| H35.3221 | Wet AMD, right eye, active CNV | If Ozurdex/IVTA was the cause → AMD still present |
| E11.3511 | T2DM with DME, right eye | If Ozurdex for DME was the cause |
| H40.1112 | Primary OAG, right eye, moderate | Only if separately documented concurrent POAG |
🛠️ CPT Templates at Moderate Stage
Template A: Established Moderate SIG — Monitoring (Outpatient)
| Code | Description | Notes |
|---|---|---|
| 92014 | Comprehensive exam, established | Full glaucoma evaluation |
| 92083 | Extended HVF 24-2 SITA Standard | Every 3–6 months at moderate stage |
| 92133 | OCT optic nerve / RNFL | Every 6 months structural assessment |
| H40.61X2 | Primary diagnosis | Moderate stage — document HVF MD value |
| T38.0X5D | Required additional | Subsequent encounter |
Template B: SLT for Moderate Drug-Induced Glaucoma
| Code | Description | Notes |
|---|---|---|
| 65855-RT | SLT, right eye | Medical necessity: H40.61X2 + inadequate IOP control on medications |
| 92014 | Exam, established | Pre-procedure evaluation |
| H40.61X2 | Primary Dx | Supports SLT medical necessity |
| T38.0X5D | Required additional |
Template C: MIGS at Cataract Surgery (Moderate Stage)
| Code | Description |
|---|---|
| 66984-RT or 66982-RT | Cataract extraction, right eye |
| 0191T-RT | iStent inject implantation (or applicable MIGS code) |
| H40.61X2 | Glaucoma Dx — supports MIGS necessity |
| H26.9 or H26.11 | Cataract code, right eye |
| T38.0X5D | Glucocorticoid adverse effect — required |
MIGS Payer Criteria Often Require "Moderate to Severe" — H40.61X2 Meets the Bar
Many payer LCD policies for iStent, Hydrus, and similar MIGS devices require documented moderate or severe glaucoma. H40.61X2 explicitly codes moderate stage — it meets this threshold. Ensure the operative note and glaucoma evaluation document the HVF MD value and IOP history supporting moderate classification.
💊 Coding Scenarios
Scenario 1 — Progression Documented from Mild to Moderate (Code Change Visit)
Clinical Vignette: Patient previously coded as H40.61X1 (mild stage) on chronic topical prednisolone for uveitis returns. HVF 24-2 OD: MD now -8.3 dB (prior -4.2 dB). New paracentral and arcuate field loss documented. Does not threaten fixation. OCT: moderate superior and inferior RNFL thinning OD. IOP 24 mmHg despite latanoprost. Physician impression: “Drug-induced glaucoma, right eye — progressed to moderate stage. Adding brimonidine. Discuss SLT at next visit.”
ICD-10-CM — Stage Upgrade:
- H40.61X2 — Glaucoma secondary to drugs, right eye, moderate stage (progression documented — MD -8.3 dB = moderate tier)
- T38.0X5D — Adverse effect of glucocorticoids, subsequent encounter (prednisolone continues)
- H20.9 — Unspecified iridocyclitis (underlying uveitis requiring steroid — document the reason steroid cannot be stopped)
Always Document WHY the Steroid Cannot Be Stopped
At moderate stage with ongoing progression, the physician note must address why the causative steroid is still being used. “Cannot discontinue prednisolone due to active uveitis” is critical documentation that supports the continued use of H40.61X2 and strengthens the medical necessity for escalated glaucoma treatment.
Scenario 2 — MIGS Performed at Moderate Stage (Concurrent Cataract Surgery)
Clinical Vignette: A 68-year-old female with drug-induced glaucoma OD (from long-term inhaled fluticasone for COPD) presents for cataract surgery. Pre-op HVF: MD -7.1 dB. OCT RNFL: moderate thinning. IOP: 22 mmHg on latanoprost + brimonidine. Surgeon performs phacoemulsification with IOL + iStent inject implantation, right eye. Impression: Moderate drug-induced glaucoma OD — MIGS performed to reduce long-term IOP medication burden.
ICD-10-CM:
- H40.61X2 — Primary — moderate drug-induced glaucoma, right eye
- T38.0X5D — Required — adverse effect glucocorticoids (inhaled fluticasone = glucocorticoid)
- H26.9 — Cataract, right eye (or more specific cataract code per documentation)
- J44.1 or J45.x — COPD / asthma — underlying reason for inhaled steroid
Inhaled Steroids + T38.0X5D
Inhaled fluticasone is still a glucocorticoid → T38.0X5D applies. Inhaled steroids carry a lower IOP-elevation risk than topical ophthalmic steroids, but the mechanism and T-code are identical. Document the steroid route in the physician note to support the causation link.
⚠️ Key Differences from H40.61X1 (Mild) — Quick Reference
| Feature | H40.61X1 Mild | H40.61X2 Moderate |
|---|---|---|
| HVF MD | > -6 dB | -6 to -12 dB |
| Monitoring frequency | Every 6–12 months HVF | Every 3–6 months HVF |
| IOP target | ≥20% reduction | ≥30% reduction |
| Surgical conversation | SLT consideration | Strong SLT/MIGS indication |
| Patient awareness | Usually asymptomatic | May notice peripheral vision loss |
| Driving safety | Usually unaffected | Discuss driving assessment |
| T-code | T38.0X5A (initial) / T38.0X5D (subsequent) | Same — T38.0X5A initial / T38.0X5D subsequent |
| Code structure | H40.61X1 | H40.61X2 |
⚠️ Coding Pitfalls and Tips
| Pitfall or Tip | |
|---|---|
| ❌ | Never submit H40.61X2 without T38.0X5x T-code — mandatory at every encounter |
| ❌ | Never assign H40.61X2 based on IOP alone — stage requires HVF and/or structural damage documentation, not IOP elevation only |
| ❌ | Never assume moderate = same monitoring schedule as mild — moderate requires more frequent HVF (3–6 months vs. 6–12 months) |
| ✅ | Moderate stage = MD between -6 and -12 dB — document the actual MD value in the note |
| ✅ | H40.61X2 supports MIGS medical necessity — explicitly codes moderate stage which meets most payer LCD criteria |
| ✅ | Same X-placeholder logic as H40.61X1 — valid, structural, required; not a deleted/missing character |
| ✅ | Stage upgrades require documentation — “progressed to moderate” or HVF printout showing MD in the moderate range |
| ✅ | T38.0X5D at monitoring visits; T38.0X5A only at first presentation of moderate stage |
| ✅ | Document why steroid cannot be discontinued — this is the most important CDI element at moderate and severe stages |
| ✅ | RT modifier on all unilateral right eye CPT codes |
📚 Sources
1. AAPC. ICD-10-CM Code H40.61 — Glaucoma secondary to drugs, right eye. Stage family H40.61X0–H40.61X4 confirmed. Use additional code instruction at H40.6 parent level confirmed.
2. ICD-10-CM FY2025 Tabular List. H40.61X2 — Glaucoma secondary to drugs, right eye, moderate stage. 7-character billable code confirmed. Mandatory T36–T50 adverse effect code instruction.
3. Hodapp E, Parrish RK, Anderson DR. Clinical Decisions in Glaucoma. Mosby: 1993. HPA criteria for mild, moderate, severe visual field staging — foundation for ICD-10-CM glaucoma stage definitions.
4. American Academy of Ophthalmology. Glaucoma Preferred Practice Pattern 2020. IOP target reduction guidelines by stage; monitoring frequency recommendations; MIGS eligibility criteria.
5. CMS LCD — Insertion of Anterior Segment Aqueous Drainage Devices (MIGS). Moderate and severe glaucoma (H40.61X2–H40.61X3) as qualifying diagnoses for iStent/Hydrus coverage. [web:198]
6. See H40.61X1 for full citation list covering pathophysiology, T-code adverse effect framework, steroid-induced glaucoma clinical background, and route-of-administration risk stratification.